Interferon γ-1b

DRUG3 trials

Sponsors

Amgen

Conditions

Friedreich's Ataxia

Phase 3

Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia

CompletedNCT02415127

AmgenFriedreich's Ataxia

Start: 2015-06-30End: 2016-11-30Updated: 2024-12-19

Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study

CompletedNCT02593773

AmgenFriedreich's Ataxia

Start: 2015-12-25End: 2017-03-21Updated: 2024-12-19

Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia

CompletedNCT02797080

AmgenFriedreich's Ataxia

Start: 2016-06-28End: 2017-03-31Updated: 2024-12-10